ROCKVILLE, Md. & CHICAGO--(BUSINESS WIRE)-- #BioTechNews--VectorBuilder, a global leader in gene del

(Editor’s note: The future prices of benchmark tracking ETFs, and the headline, the lede and the eco

US stock futures mixed, Cisco and MaxCyte report positive earnings, Alibaba and Vishay to release re

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

MaxCyte NASDAQ: MXCT reported lower first-quarter revenue compared with the prior year, as managemen

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Es

MaxCyte (NASDAQ:MXCT) affirms FY2026 sales outlook from $30.000 million-$32.000 million to $30.000 m

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.04) per share which beat the analyst consensu

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 mi

ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-en

MaxCyte, Inc. (NASDAQ: MXCT - Get Free Report) has been assigned a consensus rating of "Hold" from t

ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engi

MaxCyte (NASDAQ: MXCT) executives told investors the company made "meaningful progress" in 2025 desp

Craig-Hallum analyst Matt Hewitt maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Es

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.09) per share which met the analyst consensus

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary an

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engi

ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-eng

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-eng

MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing ena

ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leadi

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufac

MaxCyte, Inc. ( MXCT ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Mahe

MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platfo

MaxCyte (NASDAQ:MXCT) affirms FY2025 sales outlook from $29.261 million-$32.512 million to $29.261 m

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.12) per share which missed the analyst consen

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-en

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-eng

MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platf

MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technolo

MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platfor

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.12) per share which missed the analyst consen

MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support development of Adicet

Stephens & Co. analyst Helfey Hannah assumes MaxCyte (NASDAQ:MXCT) with a Overweight rating a

MaxCyte (NASDAQ:MXCT) affirms FY2025 sales outlook from $35.11 million-$37.39 million to $35.11 mill

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.10) per share which beat the analyst consensu